Topical treatment activates immune system to clear precancerous skin lesions

A combination of two FDA-approved drugs – a topical chemotherapy and an immune-system-activating compound – was able to rapidly clear actinic keratosis lesions from patients participating in a clinical trial. Standard treatment for this common skin condition, decease which can lead to the development of squamous cell carcinoma, troche takes up to a month and can elicit several unpleasant side effects.  The report from Massachusetts General Hospital (MGH) investigators has been published online and will appear in the January issue of the Journal of Clinical Investigation.

Read Full Article Here >>